Structure Therapeutics' aleniglipron extension data due after 16.2% interim win
The open-label ACCESS OLE study reports topline results in Q3 2026, testing whether the oral GLP-1 candidate's 56-week weight loss holds up as Structure moves it into Phase 3.
Executive Summary
- Structure Therapeutics is set to report topline results from an open-label extension study that has already shown weight loss continuing without a plateau, so the coming disclosure is a maturation of a result investors have seen, not a first look.
- The readout will show whether aleniglipron's weight-loss effect persists and whether tolerability holds as the dosing regimen extends toward its higher exposure levels, directly informing the dose and titration choices Structure has already committed to in its Phase 3 program.
- Aleniglipron sits in a GLP-1 receptor agonist field with the two dominant approved-class comparators, but its differentiation case rests on being an oral agent, so the durability of the effect and the tolerability of the dosing path matter more to that case than the topline percentage alone.
- The trial's own completion date has moved twice, but enrollment has held flat at its target, so the operational story is a fixed-size study extending its follow-up window, not a study in distress.
The catalyst
Structure Therapeutics said it expects to report topline results from the ACCESS open-label extension (OLE) study of aleniglipron, also known as GSBR-1290, in the third quarter of 2026. The trial, registered as NCT06693843, is a Phase 2b dose-ranging study of aleniglipron in adults with obesity or overweight and at least one weight-related comorbidity. The study is Active, not recruiting, with an enrollment target of 220 participants. Structure+1Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What is already known
The catalyst is not a first look at this data. In March 2026, Structure reported interim results from the same ACCESS OLE study showing weight loss up to 16.2% (40.5 lbs) at 56 weeks in participants on the 120 mg dose of aleniglipron, and said no weight-loss plateau had been observed across any of its aleniglipron studies. That interim update followed the separate Phase 2 ACCESS II study, which reported a placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose at 44 weeks, both with p<0.0001. Raymond Stevens, the company's chief executive, said the FDA gave positive end-of-Phase-2 feedback and set a starting titration dose of 2.5 mg for the Phase 3 program, with an intent to test multiple doses. StructureStructure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026
The endpoint bar
The trial's registered primary endpoints center on adverse events of special interest, long-term cardiac safety measured by ECG parameters, vital-sign and laboratory abnormalities, and percent change in body weight from baseline to week 36. Structure is running a supplementary arm of ACCESS OLE specifically to evaluate tolerability of a 2.5 mg starting dose in participants previously on placebo and to collect exposure data out to 72 weeks, including at the 180 mg dose. The Q3 2026 topline readout will show whether the durability and no-plateau pattern reported at 56 weeks extends further, and whether tolerability holds as dosing intensifies toward the higher end of the range. NCT06693843+1A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026
Registry timeline
The trial's primary completion date has moved twice on the registry: first pushed from October 1, 2025 to July 1, 2026 in August 2025, then pulled back to October 24, 2025 in April 2026. Enrollment has held flat at its 220-participant target throughout, which the operational risk model reads as a routine, non-significant change rather than a distress signal. The trial's overall status moved from Recruiting to Active, not recruiting in March 2025, consistent with a study that filled to target and is now following participants through its extension period. NCT06693843A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843
Competitive frame
Aleniglipron competes in an obesity field where injectable GLP-1 receptor agonists remain the dominant class, a landscape carrying 32 trials that a broader competitive scan places in the same indication. Those programs share the indication but not the modality: aleniglipron is administered orally, while the established comparators in that broader field are injectable peptides. Structure's own broader pipeline includes two not-yet-recruiting Phase 3 studies of aleniglipron, ACCOMPLISH-1 and ACCOMPLISH-2, which will enroll far larger populations of 3,600 and 1,100 participants, respectively, and depend on the dose and titration decisions this extension data is meant to support.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.